Literature DB >> 24421115

Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models.

Su-Jin Park1, Eun-Ha Kim1, Philippe Noriel Q Pascua1, Hyeok-Il Kwon1, Gyo-Jin Lim1, Arun Decano1, Se Mi Kim1, Man Ki Song2, Eui-Cheol Shin3, Young-Ki Choi1.   

Abstract

The threat of highly pathogenic avian influenza (HPAI) H5N1 viruses to cause the next pandemic remains a major concern. Here, we evaluated the cross-protection induced by natural infection of human seasonal influenza strains or immunization with trivalent inactivated influenza vaccine (TIV) against HPAI H5N1 (A/Vietnam/1203/2004) virus in ferrets. Groups were treated with PBS (group A), infected with H1N1 (group B) or H3N2 (group C) virus, or immunized with TIV (group D). Twelve weeks after the last treatment, serological assays revealed that groups B and C, but not group D, sustained moderate immunogenicity against homologous viruses; cross-reactivity against the H5N1 virus was not detected in any group. Following challenge with A/Vietnam/1203/2004 (H5N1) virus, only groups B and C exhibited attenuated viral loads leading to 100 % survival. Our data suggest that natural infection with human seasonal strains could potentially provide better heterosubtypic protection against HPAI H5N1 virus infection compared to TIV immunization.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24421115     DOI: 10.1099/vir.0.058636-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.

Authors:  Leora R Feldstein; Laura Matrajt; M Elizabeth Halloran; Wendy A Keitel; Ira M Longini
Journal:  Vaccine       Date:  2016-06-20       Impact factor: 3.641

Review 2.  Animal models for influenza viruses: implications for universal vaccine development.

Authors:  Irina Margine; Florian Krammer
Journal:  Pathogens       Date:  2014-10-21

3.  H5N1 influenza vaccine induces a less robust neutralizing antibody response than seasonal trivalent and H7N9 influenza vaccines.

Authors:  Sook-San Wong; Jennifer DeBeauchamp; Mark Zanin; Yilun Sun; Li Tang; Richard Webby
Journal:  NPJ Vaccines       Date:  2017-06-08       Impact factor: 7.344

4.  Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza.

Authors:  M D Heath; N J Swan; A C Marriott; N J Silman; B Hallis; C Prevosto; K E Gooch; M A Skinner
Journal:  BMC Infect Dis       Date:  2017-03-27       Impact factor: 3.090

5.  Infection and Rapid Transmission of SARS-CoV-2 in Ferrets.

Authors:  Young-Il Kim; Seong-Gyu Kim; Se-Mi Kim; Eun-Ha Kim; Su-Jin Park; Kwang-Min Yu; Jae-Hyung Chang; Eun Ji Kim; Seunghun Lee; Mark Anthony B Casel; Jihye Um; Min-Suk Song; Hye Won Jeong; Van Dam Lai; Yeonjae Kim; Bum Sik Chin; Jun-Sun Park; Ki-Hyun Chung; Suan-Sin Foo; Haryoung Poo; In-Pil Mo; Ok-Jun Lee; Richard J Webby; Jae U Jung; Young Ki Choi
Journal:  Cell Host Microbe       Date:  2020-04-06       Impact factor: 21.023

6.  T cell mediated immunity against influenza H5N1 nucleoprotein, matrix and hemagglutinin derived epitopes in H5N1 survivors and non-H5N1 subjects.

Authors:  Pirom Noisumdaeng; Thaneeya Roytrakul; Jarunee Prasertsopon; Phisanu Pooruk; Hatairat Lerdsamran; Susan Assanasen; Rungrueng Kitphati; Prasert Auewarakul; Pilaipan Puthavathana
Journal:  PeerJ       Date:  2021-03-10       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.